Patents by Inventor Philipp Hadwiger

Philipp Hadwiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100216866
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: March 19, 2010
    Publication date: August 26, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • Patent number: 7749978
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: July 6, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Patent number: 7737265
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: June 15, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Akin Akinc, Antonin De Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger, Birgit Bramlage
  • Patent number: 7723317
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: May 25, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • Patent number: 7674779
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: March 9, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20090312397
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: March 9, 2009
    Publication date: December 17, 2009
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • Publication number: 20090258934
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
    Type: Application
    Filed: June 18, 2009
    Publication date: October 15, 2009
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Dinah Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • Patent number: 7582745
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: September 1, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • Publication number: 20090203135
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Application
    Filed: April 23, 2008
    Publication date: August 13, 2009
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Andrea Forst, Philipp Hadwiger, Hans-Peter Vornlocher
  • Patent number: 7528118
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • Patent number: 7473525
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: January 6, 2009
    Assignee: Alnylam Europe AG
    Inventors: Roland Kreutzer, Stefan Limmer, Hans-Peter Vornlocher, Philipp Hadwiger, Anke Geick, Matthias Ocker, Christoph Herold, Detlef Schuppan
  • Publication number: 20080293662
    Abstract: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
    Type: Application
    Filed: July 10, 2008
    Publication date: November 27, 2008
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Heiko van der Kuip
  • Publication number: 20080233584
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: February 27, 2008
    Publication date: September 25, 2008
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20080221055
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: November 26, 2007
    Publication date: September 11, 2008
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Patent number: 7361752
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: April 22, 2008
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Patent number: 7320965
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: January 22, 2008
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Publication number: 20070275465
    Abstract: The invention concerns a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, whereby the sequences of the single strands of the dsRNA are selected in such a way that on both ends of the dsRNA the last complementary nucleotide pair is a G-C, or at least two of the last four complementary nucleotide pairs are G-C pairs; whereby the dsRNA exhibits a single-stranded overhang consisting of 1 to 4 unpaired nucleotides at the first end, and no overhang at the second end; whereby the unpaired nucleotide of the single-stranded overhang that is directly adjacent to the last complementary nucleotide pair contains a purine base.
    Type: Application
    Filed: June 14, 2004
    Publication date: November 29, 2007
    Applicant: Alnylam Pharmaceuticals
    Inventors: Claudia Woppmann, Hans-Peter Vornlocher, Philipp Hadwiger, Matthias John, Stefan Limmer
  • Publication number: 20070155686
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: June 27, 2006
    Publication date: July 5, 2007
    Inventors: Akin Akinc, Antonin Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20070105806
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
    Type: Application
    Filed: November 3, 2006
    Publication date: May 10, 2007
    Inventors: Dinah Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • Publication number: 20070099860
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: October 27, 2006
    Publication date: May 3, 2007
    Inventors: Dinah Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot